Trillium Therapeutics EBIT

Trillium Therapeutics (TRIL) currently reports a EBIT of $65M as of September 2021. That compares with $-210M in the prior-year period — up 130.5% year over year. That is below the Healthcare sector average of $23B. Use the charts on this page to explore Trillium Therapeutics's EBIT history and peer comparisons.

Trillium Therapeutics's EBIT increased from $-210M to $65M — a 130.5% year-over-year increase (period ending September 2021). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Trillium Therapeutics's EBIT of $65M is lower than the Healthcare sector average of $23B. That is roughly 99.7% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Trillium Therapeutics reported $65M in EBIT as of September 2021. That compares with $-210M in the prior-year period — up 130.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $65M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $23B. From there, open related valuation or income-statement pages for Trillium Therapeutics, and consider following TRIL for alerts when major investors trade the stock.